China's Phase 2 clinical trial of a new coronavirus vaccine achieves good results

Chinese researchers said in a paper published in the British medical journal The Lancet that they have conducted clinical trials of a new coronavirus vaccine that show it is safe and induces an immune responseResearchers such as DrChen Wei of the Institute of Bioengineering at the Institute of Military Medicine of the Chinese Academy of Military Sciences and Professor Zhu Fengcai of the Center for Disease Control and Prevention in Jiangsu Province conducted the clinical trialThe team has previously completed clinical trials of the vaccine and published resultsThe trial assessed a new coronavirus vaccine for adenovirus vector recombinantAccording to the paper, more than one volunteer participated in this phase of clinical trial in China, including over age compared to the phase clinical trialThe aim of the trial was to assess whether the vaccine could induce an immune response in the body and whether there was sufficient safety to show that the vaccine produced good results on both frontsIn a press release from The Lancet, Zhu said phase clinical trials provide further evidence of the safety and immunogenicity of vaccines in a wider population compared to phase clinical trials, which is an "important step" in evaluating candidate vaccines as a "significant step" in the team's ongoing phase clinical trialsThe researchers also noted that the volunteers involved in the trial were not exposed to the new coronavirus after vaccination, so it was not possible to determine whether the vaccine was effective in protecting people from the new coronavirus, and that clinical trials were needed to further validate itAccording to The Lancet, there are currently around a number of candidates for new coronavirus vaccines in the world, at least one of which is in clinical trials